Advertisement
Australia markets closed
  • ALL ORDS

    8,206.10
    +72.70 (+0.89%)
     
  • ASX 200

    7,959.30
    +69.70 (+0.88%)
     
  • AUD/USD

    0.6786
    +0.0024 (+0.35%)
     
  • OIL

    82.18
    -0.44 (-0.53%)
     
  • GOLD

    2,416.00
    -5.90 (-0.24%)
     
  • Bitcoin AUD

    87,742.34
    +2,097.62 (+2.45%)
     
  • CMC Crypto 200

    1,236.98
    +38.41 (+3.20%)
     
  • AUD/EUR

    0.6218
    +0.0001 (+0.02%)
     
  • AUD/NZD

    1.1082
    -0.0002 (-0.02%)
     
  • NZX 50

    12,134.97
    +76.68 (+0.64%)
     
  • NASDAQ

    20,331.49
    +120.13 (+0.59%)
     
  • FTSE

    8,252.91
    +29.57 (+0.36%)
     
  • Dow Jones

    40,000.90
    +247.15 (+0.62%)
     
  • DAX

    18,748.18
    +213.62 (+1.15%)
     
  • Hang Seng

    18,293.38
    +461.05 (+2.59%)
     
  • NIKKEI 225

    41,190.68
    -1,033.34 (-2.45%)
     

Ocular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Ocular Therapeutix (NASDAQ:OCUL) Full Year 2022 Results

Key Financial Results

  • Revenue: US$51.5m (up 18% from FY 2021).

  • Net loss: US$71.0m (loss widened by US$64.5m from FY 2021).

  • US$0.92 loss per share (further deteriorated from US$0.086 loss in FY 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ocular Therapeutix Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 3.7%.

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in the US.

ADVERTISEMENT

Performance of the American Pharmaceuticals industry.

The company's shares are down 3.2% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Ocular Therapeutix that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here